As life expectancy continues to expand for cancer patients, clinicians are increasingly dealing with oncological complications like cardiotoxicity, according to a medical team in the Netherlands—and those doctors are met with a paucity of research on the topic.

Tracking the fate of 200 unsolicited manuscripts rejected in one calendar year by the American Journal of Roentgenology, a researcher has found that the majority—117 manuscripts, close to 60 percent—eventually found a home in other scientific journals, according to an analysis running in the June edition of that very journal. 

Architectural distortion, the non-mass but potentially ominous clinical feature observed in many breast imaging procedures, is less likely to signal malignancy when it’s detected on screening mammography rather than diagnostic mammography or when it does not correlate with a subsequent targeted ultrasound exam.

While amyloid imaging is typically discussed with regard to diagnosing Alzheimer’s disease, a team of French researchers, presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015 annual meeting, have found that amyloid scans of the heart can predict major cardiac events.

Significantly fewer renal and cardiac events are associated with angioplasty procedures using isosmolar contrast medium (IOCM) agent Visipaque (iodixanol) than those using low-osmolar contrast media (LOCM), demonstrate data from abstracts presented today at the EuroPCR Congress 2015 in Paris. 

Germany's ground-breaking use of CT scanners in ambulances to assess for possible stroke inspired one program in Houston to follow suit. Supporters predict it will transform care in the future. 

Cocaine addiction can ruin a person physically and financially, and with an estimated 1.4 million cocaine users in the U.S., thousands will become trapped by their habit. While previous research on the drug and its addictive potential were observational and subjective, imaging is reshaping how we see addiction—and how it will be treated.

REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") announced initial clinical results from patients treated with its ReZolve2 sirolimus-eluting bioresorbable coronary scaffold at Transcatheter Therapeutics 2013 ("TCT"), the world's leading interventional cardiology conference, which is being held this week in San Francisco, California. The ReZolve2 trial is currently enrolling up to 125 patients at multiple centers in Australia, Brazil, Europe, and New Zealand to provide the data needed to apply for European CE Marking. Patient enrollment was initiated in March 2013 and is currently ongoing.